Eli Lilly aka LLY hit a new all time high again on Wednesday after rival GLP1 drugmaker Novo Nordisk announced it was ending a kidney failure study early for its drug semaglutide due to efficacy data. Shares of Lilly set a 52 week high of $608.7 before closing the session 5% higher at $605.28. Shares of Novo Nordisk increased as well, rising 6% to settle at...
There is a high probability that it can hit 250 in next 3 months, it must break above 170 first. Some big news around 170 can make it hit 250.
Johnson & Johnson, together with its subsidiaries, researches, develops, manufactures, and sells various products in the healthcare field worldwide. The company's Consumer Health segment provides skin health/beauty products under the AVEENO, CLEAN & CLEAR, DR. CI:LABO, NEUTROGENA, and OGX brands; baby care products under the JOHNSON'S and AVEENO Baby brands; oral...
Walgreens on the weekly chart here is breaking out. I'd go long here anticipating a breakout over 52$ and if it holds it'll begin a nxt run up.
Pharmaceutical company these are starting to become my new drug. Propah gains to be made! This thing moves fast af! bullish all the way.
With the rapidly expanding prescription drug market, one may take a flyer out on this stock (Rite Aid). As most of you know Rite Aid sold a vast amount of their stores to Walgreens, but the real story is those stores that were sold were in key geographic locations and created large amounts of revenue. I have been tracking this stock since 2013, and the common...
$CBIO Recent Highlights and Upcoming Milestones Recent Highlights: Catalyst Biosciences’ Factor IX Recommended for Orphan Drug Designation in Europe Contract revenue for the three months ended March 31, 2017 was $0.3 million, compared with $0.1 million for the prior year period. The increase in contract revenue was due to the milestone revenue from ISU Abxis...
There is one useful way to determine when a trend is over and that is using a 50% "speedline" of a move. The decline from $400 in $IBB, the IShares Nasdaq Biotechnology Index Fund back in July 2015 and then tumbled 40% to $240 on February 9th, 2016 and later retested $240 on June 27, 2016. The mid-point of that decline is $320 and a line drawn from...
specialty drug strong group-new cep-stick with strong groups
strong bar-diversify-5 percent-use limits-trailing stop loss close below 8 ema goal line
almost out of cloud-diversify-dynamic stop loss 8 ema-no mrs then 5 percent in ideas keep 25 percent of powder dry-get our book on money management-watch our weekly tube on sunday night
no new antibodict drugs in ten years- needed 40 percent reject rate with z pack- web site and chat room coming labor day get in early -money flow excellent-like concept stocks-dmi strong-macd crossed -adx trending-trailing stop loss 20 ema
j hook pattern see the reason why the shape is important in our book relative strength excellent cci and percent r rising watch 50 day ma